News from oncosec medical incorporated A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 23, 2022, 08:00 ET OncoSec Receives Triple Negative Breast Cancer Foundation's Vanguard Award for Excellence in Oncology Research

OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec") today announced that it is the recipient of the 2022 Vanguard Award...

Apr 29, 2022, 08:00 ET OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer

OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral...

Feb 22, 2022, 17:59 ET OncoSec Announces Appointment of George Chi as Chief Financial Officer

OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral...

Dec 17, 2021, 09:09 ET OncoSec Announces Changes to its Board of Directors

OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing cytokine-based ...

Nov 02, 2021, 08:00 ET OncoSec Medical Hosting SITC Key Opinion Leader Webinar on Updated Data from the KEYNOTE-695 Study

OncoSec Medical Incorporated (NASDAQ: ONCS) will host a conference call and webcast for investors and analysts on Friday, November 12 at 7:00 AM ET...

Oct 20, 2021, 16:02 ET OncoSec Provides Business Update

OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing cytokine-based ...

Aug 16, 2021, 16:01 ET OncoSec Provides Leadership Update

OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the establishment of a Leadership Committee consisting of...

Jul 26, 2021, 08:30 ET OncoSec to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference

OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that Interim CEO and Chief Operating Officer, Brian Leuthner, ...

Jul 06, 2021, 16:01 ET OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO™ Combined with KEYTRUDA® for Late-Stage Metastatic Melanoma

OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced it has entered into a Clinical Trial Collaboration and Supply ...

Jun 24, 2021, 16:30 ET OncoSec Appoints Brian Leuthner as Interim Chief Executive Officer

OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that Daniel O'Connor has resigned and that Brian Leuthner,...

Jun 14, 2021, 08:30 ET OncoSec Appoints Industry Leading Electroporation Device Expert, Jeffrey Silverman, as Vice President of Product Engineering

OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), today announced the appointment of Jeffrey Silverman as Vice President of...

May 27, 2021, 08:30 ET OncoSec to Present at the Raymond James Human Health Innovation Conference

OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that management will present a company overview at the...

May 17, 2021, 08:30 ET OncoSec Appoints Robert M. Schinagl, Ph.D. as Vice President of Program and Alliance Management

OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the appointment of Robert M. Schinagl, Ph.D., a biotech...

Apr 15, 2021, 08:30 ET OncoSec to Present Encore Interim Data from the KEYNOTE-695 Phase 2b Clinical Trial at the 10th World Congress of Melanoma

OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a biotechnology company focused on cytokine-based intratumoral...

Apr 14, 2021, 08:30 ET OncoSec Receives CE Mark Certification for its Commercial Electroporation Device "GenPulse™" for the Treatment of Solid Tumors

OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a biotechnology company focused on cytokine-based intratumoral...

Mar 25, 2021, 08:39 ET OncoSec Medical Sponsoring KOL Webinar On A High Unmet Medical Need: Anti-PD-1 Checkpoint Refractory Metastatic Melanoma

OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a biotechnology company focused on cytokine-based intratumoral cancer...

Mar 01, 2021, 09:00 ET OncoSec Announces Publication in Clinical Cancer Research of Data Supporting the Therapeutic Potential of Lead Product Candidate, TAVO™, in Triple Negative Breast Cancer

OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company focused on cytokine-based intratumoral...

Feb 23, 2021, 09:00 ET OncoSec Announces Approval of $2.5 Million in NJEDA NOL Program Tax Benefits

OncoSec Medical Incorporated ("OncoSec") (Nasdaq:ONCS), a late-stage biotechnology company focused on designing, developing and commercializing...

Feb 18, 2021, 08:30 ET OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development

OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the appointment of Bridget O'Keeffe, Ph.D., a biotech...

Feb 02, 2021, 09:00 ET OncoSec Strengthens Management Team With Two New Appointments

OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the addition of two new executives to the company's...

Jan 27, 2021, 09:00 ET OncoSec Announces First Subjects Dosed in Phase 1 Trial of CORVax12, OncoSec's COVID-19 Vaccine Candidate Combining Interleukin-12 (IL-12) with an Enhanced SARS-CoV-2 Spike Protein

OncoSec Medical Incorporated (NASDAQ: ONCS) today announced that it has dosed several subjects in its Phase 1 clinical trial of CORVax12, the only...

Jan 25, 2021, 16:00 ET OncoSec Medical Closes $42.0 Million Public Offering of Common Stock

OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company focused on designing, developing and...

Jan 21, 2021, 08:30 ET OncoSec Medical Announces Pricing of $42.0 Million Public Offering of Common Stock

OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company focused on designing, developing and...

Jan 20, 2021, 16:35 ET OncoSec Medical Announces Proposed Public Offering of Common Stock

OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company focused on designing, developing and...

Jan 19, 2021, 08:30 ET OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO™

OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced it entered into an agreement with Sirtex Medical, Inc....